You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》交銀國際:醫藥板塊擁多重利好 趨勢穩中向好
交銀國際發表研究報告指,醫藥板塊行情穩中向好,今年可望成為關鍵轉折之年。當中政策短期擾動基本出清,更多利好政策可望落實,而行業未來兩年盈利高增長確定性強,短期盈利預測逐步上調,另創新藥出海熱潮延續亦是利好因素。
對於下半年,該行認為醫藥板塊受宏觀環境復甦、降息周期及政策利好帶動,後續機會將來自當前仍被低估、長期增長空間清晰及催化劑豐富的個股。
創新藥方面,該行預期龍頭生物科技企業將集中迎來損益平衡轉捩點,推薦康方生物(09926.HK)、榮昌生物(09995.HK)、科倫博泰(06990.HK)。至於處方藥板塊,該行籲關注短期業績增長和具長期創新增值空間的個股,重點推薦先聲藥業(02096.HK)。另外,CXO方式看好藥明合聯(02268.HK)和金斯瑞(01548.HK)。對於民營醫院領域,則推薦短期增長確定性強及長期擴張路徑清晰的固生堂(02273.HK)和海吉亞醫療(06078.HK),同時關注政策紅利效應顯著的錦欣生殖(01951.HK)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.